tbuckley/cabot-search huggingface dataset:
Epigenetic Profiling Of Leukemia Stem Cells In a Model Of TET2/FLT3-Mutant AML
Authors: Alan H. Shih, Yanwen Jiang, Kaitlyn Shank, Suveg Pandey, Agnes Viale, Yongming Sun, Nicholas Socci, Alexander Robertson, Elisa de Stanchina, Todd Hricik, Franck Rapaport, Brittany Woods, Luisa Cimmino, Laura Barreyro, Ulrich Steidl, Iannis Aifantis, Ari Melnick, Ross L. Levine
Journal: Blood (2013)
Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.
Authors: Francesca Gay, Suzanne Hayman, Martha Q. Lacy, Francis Buadi, Morie A Gertz, Shaji Kumar, Angela Dispenzieri, Joseph R. Mikhael, Leif Bergsagel, David Dingli, Craig B. Reeder, John A. Lust, Stephen Russel, Vivek Roj, Steven R. Zeldenrust, Thomas E. Witzig, Rafael Fonseca, Robert Kyle, Philip R. Greipp, A. Keith Stewart, S. Vincent Rajkumar
Journal: Blood (2009)
Association of transcription factor 7-like 2 (TCF7L2) polymorphisms with worse survival in three independent cohorts from the United States, Austria, and Japan in patients with gastric cancer.
Authors: Rita Elie El-Khoueiry, Takeru Wakatsuki, Yan Ning, Wu Zhang, Dongyun Yang, Mizutomo Azuma, Armin Gerger, Michael Stotz, Melissa Janae Labonte, Peter M. D. Wilson, Nico Benjamin Volz, Sebastian Stintzing, Martin K. H. Maus, Yu Sunakawa, Wasaburo Koizumi, Masahiko Watanabe, Joseph Ethan Li, Afsaneh Barzi, Anthony B. El-Khoueiry, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2013)

4111 Background: The Wnt/β-catenin signaling pathwaycontrols cell proliferation and differentiation. Disruption of this pathway has been shown in the majority of colorectal (CRC) and gastric cancer (GC). The TCF7L2 complex plays a critical role in this pathway. Interaction of TCF7L2 and β-catenin results in translocation to the nucleus and leads to up-regulation of target genes, including c-myc and cyclin D1. Previous reports have shown that TCF7L2 polymorphism rs7903146 C/T is associated with CRC risk and outcome; however, the prognostic role of this polymorphism in GC is unknown. Therefore, we tested the hypothesis of whether this polymorphism could predict outcome in GC in three independent cohorts. Methods: A total of 369 patients (pts) with histopathologically-confirmed localized GC were enrolled from Japan (n=169), the US (n=137), and Austria (n=63) between 2002 and 2010. Results: In the US cohort, pts with at least one-T allele ((T/T or C/T; n=46) showed a median TTR of 1.7 yrs vs. 4.4 yrs compared to pts homozygous C/C (n=76) (HR: 2.09 95%CI: 1.21- 3.59, p=0.0053). A similar trend was shown in the Austrian cohort, where pts harboring at least one-T allele (n=25) showed a median DFS of 2.08 yrs vs. 5.42 yrs for pts homozygous C/C (n=38) (HR: 1.79 [95%CI: 0.90-3.55], p=0.092). Moreover, in the Japanese cohort, pts homozygous for T/T demonstrated (n=2) a median DFS of 0.15 yrs vs. 4.82 yrs for pts harboring at least one-C allele (n=165) (HR: 10.5 [95%CI: 2.46-45.5], p=0.001). These results were confirmed in the OS in the US and Japanese cohorts. Pts at least one-T allele (n=46) showed a median OS of 3.3 yrs vs. 5.5 yrs for pts homozygous C/C (n=76) (HR: 2.41 95%CI: 1.28-4.53, p=0.0043) in the US cohort, while pts homozygous T/T showed (n=2) a median OS of 0.22 yrs vs 5.76 yrs for pts harboring at least one-C allele (n=165) (HR: 15.2 [95%CI: 3.50-66.7], p&lt;0.001). Conclusions: TCF7L2 polymorphism was associated with worse prognosis in recurrence in pts with GC in three independently global cohorts. This polymorphism may be negative prognostic factor in GC regardless of ethnicity and etiology, suggesting the importance role of Wnt/β-Catenin signaling in GC.
Final Evaluation Of a Prospective, Non-Interventional Study On Efficacy and Tolerability Of a New Generation VWF/FVIII Concentrate In The Treatment Of Von Willebrand Disease
Authors: Sonja Alesci, Mario Von Depka, Jennifer Feddern, Susan Halimeh, Oliver Hegener, Janos Kadar, Wolfgang A. Miesbach, Ulrike Nowak-Göttl, Inge Scharrer
Journal: Blood (2013)
Identification of DEEP Vein Thrombosis GENETIC RISK Variants by NEXT GENERATION Sequencing of Hemostatic Genes
Authors: Luca Andrea Lotta, Mark Wang, Jin Yu, Fuli Yu, Ida Martinelli, Serena Passamonti, Emanuela Pappalardo, Marzia Menegatti, Lora L Lewis, Walker Hale, Donna M Muzny, Pier Mannuccio Mannucci, Richard A Gibbs, Flora Peyvandi
Journal: Blood (2011)
Thromboembolism and Clinically Relevant Bleeding in Relation to Warfarin Anticoagulation Variability in Patients Monitored with Either Fiix-Prothrombin Time or Quick-Prothrombin Time. the Fiix-Trial
Authors: Alma R. Oskarsdottir, Brynja R. Gudmundsdottir, Olafur S. Indridason, Hulda M. Jensdottir, David O. Arnar, Einar S. Bjornsson, Magnus K. Magnusson, Sigrun H. Lund, Brynjar Vidarsson, Charles W. Francis, Pall T. Onundarson
Journal: Blood (2015)
A Multicenter Randomized Clinical Trial Comparing a Powered Bone Marrow Biopsy System and Manual Bone Marrow Biopsy Procedures.
Authors: James R. Berenson, Ori Yellin, Deanna Bojanower, Croopnick Jonathan, David Aboulafia, Gargi Upadhyaya, Brent Blumenstein
Journal: Blood (2010)
HLA Genetic Risk Burden in Multiple Sclerosis
Authors: Mark Mühlau, Till F. M. Andlauer, Bernhard Hemmer
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Refining the Diagnosis of Type 2 Myocardial Infarction—Reply
Authors: Peter Nagele
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Intraductal Papillary Mucinous Neoplasm of the Pancreas With High Malignant Potential on FDG PET/MRI
Authors: Li Huo, Feng Feng, Quan Liao, Zhengyu Jin, Fang Li, Yupei Zhao
Journal: Clinical Nuclear Medicine (2016)

A 57-year-old man underwent FDG PET/CT to evaluate a mass in the head of the pancreas. The imaged revealed mildly, nonuniformly increased activity in the mass, but the exact location of the activity could not be determined on the low-dose noncontrast CT portion of the study. On subsequent PET/MRI images acquired 60 minutes after the FDG PET/CT study, the increased activity was clearly localized on the cystic wall. The pathological examination showed that the lesion was intraductal papillary mucinous neoplasm of the pancreas with high degree of dysplasia.
The Chemotactic Lipid S1P Regulates Hematopoietic Progenitor Cell Egress and Mobilization Via Its Major Receptor S1P1 and by SDF-1 Inhibition In a p38/Akt/mTOR Dependent Manner
Authors: Karin Golan, Yaron Vagima, Aya Ludin, Tomer Itkin, Alexander Kalinkovich, Shiri Cohen-Gur, Orit Kollet, Amir Schajnovitz, Shoham Shivtiel, Tsvee Lapidot
Journal: Blood (2010)
Effect of small molecule Magmas inhibitor (SMMI) on human glioblastoma multiforme cell line apoptosis.
Authors: P. Jubinsky, B. Das, A. Vortmeyer, M. Short
Journal: Journal of Clinical Oncology (2010)

e13547 Background: Magmas was identified as a growth factor inducible gene in the myeloid cell line PGMD1. An essential nuclear encoded mitochondrial protein that associates with the translocase of the inner mitochondrial membrane (TIM 23), Magmas is required for protein import into the mitochondria and cell growth and survival. Magmas expression in several types of human tumors has been shown to be significantly higher than the levels present in normal tissues. In prostate cancer, this is due to an increased amount of Magmas per mitochondria and not more mitochondria per cell. Mitochondria have critical roles in numerous cellular processes, including redox homeostasis and apoptosis. Regulation of mitochondrial function by inhibiting Magmas could be a novel approach for treating tumors that currently lack effective therapies, such as glioblastoma multiforme (GBM). Methods: A site important for Magmas activity was identified by sequence homology and functional mutagenesis. Using structural data and molecular modeling, compounds designed to bind to Magmas were synthesized. The compounds were screened for biological activity on GBM cell lines. The most active compound (SMMI) was tested for functional interactions with Magmas. Results: Several of the compounds designed to interact with Magmas were found to inhibit the growth of GBM cell lines. This inhibition occurred at much lower concentrations than those required to inhibit the proliferation of the control primary human umbilical vascular endothelial cells. SMMI was active at 1 uM and resulted in cell cycle arrest at lower concentrations or cell death at higher concentrations. Target specificity was demonstrated by direct binding of SMMI to Magmas as well as detecting an altered SMMI dose response in cells containing mutated or over-expressed Magmas. Conclusions: A Magmas inhibitor was synthesized and shown to directly bind and functionally interact with Magmas. SMMI had greater biological activity against GBM lines than primary cells suggesting that it could have potential clinical applications in the treatment of these aggressive brain tumors. No significant financial relationships to disclose.
Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp)
Authors: Alessandra Oliva, L. Scorzolini, D. Castaldi, F. Gizzi, M. De Angelis, M. Storto, A. D'Abramo, F. Aloj, M.T. Mascellino, C.M. Mastroianni, V. Vullo
Journal: Journal of Infection (2016)
Concurrent chemoradiotherapy (CRT) following neoadjuvant chemotherapy (NACT) in locally advanced breast cancer (LABC)
Authors: A. Alvarado-Miranda, R. Morales-Barrera, O. Arrieta, J. Zinser-Sierra, A. Gamboa-Vignole, E. Maafs-Molina, T. Ramirez-Ugalde, F. Lara-Medina
Journal: Journal of Clinical Oncology (2007)

11063 Background: Despite broad advances in the treatment of LABC, 30 to 40% of patients responding to NACT develop locoregional relapse. We performed a retrospective analysis of the experience obtained so far in patients with LABC who were treated with CRT after NACT in terms of pathologic complete response (pCR), relapse-free survival (RFS) and overall survival (OS) at our institution. Methods: One hundred and twelve patients with LABC (Stage IIB-IIIB) were treated between January 2000 and December 2003 with NACT with 5FU 500mg/m 2 , doxorubicin 50 mg/m2 and cyclophosphamide 500mg/m 2 (FAC) or doxorubicin 50 mg/m 2 and cyclophosphamide 500mg/m 2 (AC) administered i.v. in four 21-day cycles. CRT with 60 Gy whole-breast irradiation and concurrent weekly mitomycin 5mg, 5FU 500mg and dexamethasone 16 mg or cisplatin 30 mg, gemcitabine 100 mg and dexamethasone 16 mg. Subsequently they underwent surgery and 6 to 8 weeks later received 2 additional courses of FAC, AC or paclitaxel 90mg weekly for 12 weeks and in estrogen receptor (ER) positive patients hormone therapy. Results: Median tumor size 5 cm; stages IIB, IIIA and IIIB were 21.4%, 42.9% and 35.7% respectively. pCR was 42% (CI 95% 33.2 - 50.5) in breast and 29.5% (CI 95% 21.4 - 37.5) in breast and axillary lymph nodes. Multivariate analysis showed the main determinant of pCR was negative ER (P 0.016). Median RFS has not been reached. The 5 year RFS is 76.9% (CI 95% 68.2 - 84.7). No relationship between pCR and RFS was found. Multivariate analysis showed the main determinant of RFS was the clinical stage (p=0.03). Only one patient had local recurrence. The 5 year OS is 84.2% (CI 95% 75 - 93.2). Toxicity during CRT: grade 1–2 neutropenia 32.2%, grade 1–2 anemia 5.2%, grade 3 radioepithelitis 22.4% Conclusions: This modality has good locoregional control for locally advanced breast cancer with an acceptable toxicity profile. Futher investigation of concurrent chemoradiotherapy should be explored in LABC. No significant financial relationships to disclose.
Thrombotic and Hemorrhagic Events for Patients on Pediatric Oncology Group (POG) Protocols 9201, 9605, 9406.
Authors: Megan A. Rice, Beverly A. Bell, Allen Chauvenet, Joanne Kurtzberg, Sharon B. Abish, Jeanette Pullen, Meenakshi Devidas, Bruce M. Camitta
Journal: Blood (2005)
Dutch perspective
Authors: Albert J J A Scherpbier
Journal: BMJ (2006)

affected.So what do medical educators at undergraduate and postgraduate level need to be doing now?In essence we need a reality check on purpose and practicalities.x Do we have enough flexibility to future proof for technological advances, demographic changes, and new government policies?Ensuring the health service has the right capabilities and capacity is everybody's business.Medical education and training prepare doctors for their future roles, and their leaders must have a vision of those roles and an understanding of their context.The changes occurring in England are not unique.Patient pressure for choice, diversity of healthcare providers, and extended roles of other staff are realities in many countries.The lessons learnt here about maintaining and strengthening medical education will be applicable elsewhere.Contributors and sources: LH has specific remit for workforce, education, and training issues in the Office of the Strategic Health Authorities, including the support and management of collective working of postgraduate medical deans and GP directors of education.The views
Oral mucositis is associated with increased resource use among patients receiving treatment for cancers of the head and neck
Authors: D. M. Keefe, A. Garden, A. Barasch, R. Tischler, M. Brennan, A. Trotti, M. Vera-Llonch, G. Oster, L. Elting, S. Sonis
Journal: Journal of Clinical Oncology (2007)

6070 Background: Oral mucositis (OM) is the oral manifestation of mucosal injury (MUI), and is a common, bothersome, and treatment-interrupting toxicity of chemoradiation therapy for squamous cell cancers (SCC) of the head and neck. Retrospective studies have reported that OM increases healthcare resource use. We present interim results of an international, multicenter, prospective study undertaken to characterize the clinical and economic burden of OM in patients with cancers of the oral cavity (OC), oropharynx (OP), larynx (L) and hypopharynx (HP). Methods: Patients (pts) with histologically proven SCC of the designated anatomical sites, whose planned treatment included full-cycle conventional or intensity modulated (IM) radiation therapy (RT) with or without chemotherapy, were enrolled at least one week prior to the start of treatment. Pts completed the Oral Mucositis Daily Questionnaire (OMDQ), a validated questionnaire developed to document patient-reported symptoms of OM and MUI including mouth and throat soreness (MTS), at baseline and daily throughout RT. MTS was assessed using a 5-point numeric rating scale, ranging from 0 (“no soreness”) to 4 (“extreme soreness”). Results: Of the first 61 pts to complete RT, 72% had cancers of the OC or OP, 49% received IMRT with concomitant chemotherapy, and 68% were male. 95% of pts reported OM symptoms (MTS&gt;0); 80% had one or more scores =2. Pts with OC or OP cancers reported more symptoms than those with L or HP tumors (mean maximum score: 3.3 vs 2.8; p= 0.12). MTS scores were positively related to levels of resource use. Conclusions: Symptoms of radiation-induced OM are positively correlated with levels of resource utilization in patients with head and neck cancers. No significant financial relationships to disclose. [Table: see text]
Results of T Cell Depleted (TCD) Myeloablative Hematopoietic Stem Cell Transplants (HSCT) in Patients with Hematologic Malignancies ≥ 55 yrs of Age.
Authors: Ann A. Jakubowski, Esperanza B. Papadopoulos, Hugo R. Castro-Malaspina, Katharine Hsu, Miguel-Angel Perales, Marcel Van den Brink, James W. Young, Richard J. O’Reilly
Journal: Blood (2005)
Dispelling the myth that chronic pain is unresponsive to treatment
Authors: Bruno T Saragiotto, Chris G Maher, Adrian C Traeger, Qiang Li, James H McAuley
Journal: British Journal of Sports Medicine (2016)

The contemporary management of chronic pain is strongly influenced by the belief that the non-pain consequences (eg, disability, emotional distress and reduced quality of life) play the dominant role in the experience of chronic pain.1 ,2 For example, treatments, such as education and biopsychosocial rehabilitation (ie, acceptance and commitment therapy), focus on reducing disability and distress, rather than pain intensity.

Growing use of non-pain-targeted approaches has seen the emergence of a view that treatments for chronic pain have little or no effect on pain, but have larger effects on non-pain factors such as disability.3 Patients are told to accept their pain and not to expect it to improve with treatment. This view is well illustrated in the quote:4 “Our best chronic-pain treatments don't produce an immediate or substantial change in pain intensity. Multimodal therapy… is not titrated to pain intensity but has a primary goal of reducing pain related distress, disability, and suffering. When it does that successfully, a reduction in pain intensity might follow—or acceptance might make the intensity of pain less important to a person's functioning and quality of life…We …
Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.
Authors: B. E. Johnson, A. J. Ryan, J. Heymach, C. Stephens, S. J. Kennedy, P. B. Langmuir, R. S. Herbst
Journal: Journal of Clinical Oncology (2010)

7516 Background: VAN is a once-daily oral inhibitor of VEGFR, EGFR, and RET signaling. VAN (100 mg/day) + D significantly prolonged PFS in ZODIAC, which included prospective exploratory analyses of potential relationships between clinical outcome and tumor biomarkers. Methods: Pts (n=1,391) with stage IIIB/IV NSCLC (mean age, 58 yrs; 30% female; any histology) were randomized to VAN + D or D + placebo (P). Prespecified analyses were performed on archival tumor samples (n=570) from consenting pts (n=958): EGFR protein expression by immunohistochemistry (IHC, n=362), EGFR gene copy number by fluorescent in situ hybridization (FISH, n=348), and EGFR (n=347) and KRAS (n=330) gene mutation status (wild-type [WT] or mutation [MT]) by the ARMS assay. Results: Baseline characteristics of pts with evaluable tumor samples were generally consistent with all pts. High EGFR protein expression (≥1% tumor cells stained, IHC+) was detected in 318 (88%) evaluable samples, 123 (35%) samples were FISH+ (defined as high EGFR gene polysomy or EGFR gene amplification), 50 (14%) samples had EGFR MT (exons 18–21), and 43 (13%) samples had KRAS MT (exons 12–13). Consistent trends toward improved PFS, overall survival and objective response rate for pts with EGFR FISH+ or EGFR MT tumors were seen with VAN + D vs D + P (Table). No consistent trends for differential benefits were associated with EGFR protein expression or KRAS mutation status. Conclusions: Exploratory analyses suggest that EGFR gene copy number (FISH+) and EGFR mutation status (EGFR MT) may have some predictive value in identifying pts who receive most benefit from VAN + D in second-line NSCLC. n PFS OS ORR HR, 97.58% CI HR, 97.52% CI HR, 97.5% CI All 1,391 0.79, 0.70–0.90 0.91, 0.78–1.07 1.84, 1.29–2.64 EGFR IHC+ 318 0.80, 0.61–1.04 0.77, 0.55–1.07 1.68, 0.84–3.39 IHC- 44 0.82, 0.38–1.79 1.08, 0.45–2.62 2.17, 0.30–15.85 FISH+ 123 0.61, 0.39–0.94 0.48, 0.28–0.84 3.90, 1.02–14.82 FISH- 225 1.20, 0.87–1.65 1.13, 0.78–1.64 1.20, 0.46–3.10 MT 50 0.51, 0.25–1.06 0.46, 0.14–1.57 3.34, 0.80–13.89 WT 297 0.99, 0.76–1.31 0.93, 0.67–1.28 0.98, 0.41–2.33 KRAS MT 43 1.04, 0.51–2.15 0.78, 0.35–1.75 1.81, 0.11–30.83 WT 287 0.75, 0.57–1.00 0.87, 0.61–1.22 1.88, 0.89–3.97 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration AstraZeneca AstraZeneca AstraZeneca AstraZeneca Genzyme
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
Authors: Jesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, Meral Beksac, Meletios A Dimopoulos, Ashraf Elghandour, Wieslaw W Jedrzejczak, Andreas Günther, Thanyaphong N Nakorn, Noppadol Siritanaratkul, Robert L Schlossman, Jian Hou, Philippe Moreau, Sagar Lonial, Jae H Lee, Hermann Einsele, Monika Sopala, Bourras-Rezki Bengoudifa, Florence Binlich, Paul G Richardson
Journal: The Lancet Haematology (2016)
Lack of Association of Mutations in IDH1, IDH2, DNMT3A with Outcome in Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents (± Histone Deacetylase Inhibitors).
Authors: Farhad Ravandi, Keyur P. Patel, Rajyalakshmi Luthra, Sherry A. Pierce, Gautam Borthakur, Elias J. Jabbour, Tapan M. Kadia, Naveen Pemmaraju, Naval Daver, Marina Konopleva, Stefan Faderl, Guillermo Garcia-Manero, Jorge E Cortes, Hagop M. Kantarjian
Journal: Blood (2012)